Cargando…

Asymmetric Dimethylarginin (ADMA) as a Marker of Endothelial Dysfunction in Primary Aldosteronism

BACKGROUND: Recent studies have revealed a higher rate of cardiovascular complications in primary aldosteronism (PA) compared to patients with essential hypertension (EH). Asymmetric dimethylarginine (ADMA) is a marker of endothelial dysfunction that could contribute to increased cardiovascular risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matrozova, Joanna, Vasilev, Vladimir, Vandeva, Silvia, Elenkova, Atanaska, Kirilov, Georgi, Zaharieva, Sabina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237362/ https://www.ncbi.nlm.nih.gov/pubmed/28123434 http://dx.doi.org/10.5812/ijem.30324

Ejemplares similares

Asymmetric Dimethylarginine (ADMA) and Endothelial Dysfunction: Implications for Atherogenesis
por: Landim, Maurício Batista Paes, et al.
Publicado: (2009)

The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
por: Sibal, Latika, et al.
Publicado: (2010)

Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
por: Tain, You-Lin, et al.
Publicado: (2017)

Case Report: A case report of acromegaly associated with primary aldosteronism
por: Matrozova, Joanna, et al.
Publicado: (2014)

Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes
por: Tsikas, Dimitrios, et al.
Publicado: (2018)

Macroprolactinemia in a Patient with Invasive Macroprolactinoma: A Case Report and Minireview
por: Elenkova, Atanaska, et al.
Publicado: (2013)

Biological Functional Relevance of Asymmetric Dimethylarginine (ADMA) in Cardiovascular Disease
por: Franceschelli, Sara, et al.
Publicado: (2013)

Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD)
por: Scott, Jeremy A., et al.
Publicado: (2014)

Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA) Concentrations in Patients with Obesity and the Risk of Obstructive Sleep Apnea (OSA)
por: Arlouskaya, Yana, et al.
Publicado: (2019)

Plasma-free metanephrines, nerve growth factor, and renalase significance in patients with PCOS
por: Robeva, Ralitsa, et al.
Publicado: (2023)

Evaluation of Asymmetric Dimethylarginine (ADMA) Levels in Children with Growth Hormone Deficiency
por: Önder, Aşan, et al.
Publicado: (2014)

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
por: Oliva-Damaso, Elena, et al.
Publicado: (2016)

Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality
por: Nijveldt, RJ, et al.
Publicado: (2003)

Symmetrical (SDMA) and asymmetrical dimethylarginine (ADMA) in sepsis: high plasma levels as combined risk markers for sepsis survival
por: Winkler, Martin Sebastian, et al.
Publicado: (2018)

Asymmetric dimethylarginine (ADMA) is identified as a potential biomarker of insulin resistance in skeletal muscle
por: Lee, Woojung, et al.
Publicado: (2018)

Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach
por: Oliva-Damaso, Elena, et al.
Publicado: (2019)

Alterations of Asymmetric Dimethylarginine (ADMA)-Containing Protein Profiles Associated with Chronic Pancreatitis Pathogenesis
por: Tan, Chaochao, et al.
Publicado: (2021)

Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease
por: Aldámiz-Echevarría, Luis, et al.
Publicado: (2012)

Asymmetric Dimethylarginine (ADMA) Levels Display a Morning Peak in Patients with Acute Myocardial Infarction
por: Bergheanu, Sandrin C., et al.
Publicado: (2011)

Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy
por: Nemeth, Zoltan, et al.
Publicado: (2015)

Asymmetric Dimethylarginine (ADMA) in Pediatric Renal Diseases: From Pathophysiological Phenomenon to Clinical Biomarker and Beyond
por: Hsu, Chien-Ning, et al.
Publicado: (2021)

The role of asymmetric dimethylarginine (ADMA) in COVID-19: association with respiratory failure and predictive role for outcome
por: Sozio, Emanuela, et al.
Publicado: (2023)

Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients
por: Stanisavljevic, Natasa, et al.
Publicado: (2022)

Cadmium-induced endothelial dysfunction mediated by asymmetric dimethylarginine
por: Al-Naemi, Hamda A., et al.
Publicado: (2020)

Asymmetric dimethylarginine (ADMA), nitric oxide metabolite, and estradiol levels in serum and peritoneal fluid in women with endometriosis
por: Kianpour, Maryam, et al.
Publicado: (2015)

The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood–brain barrier in vitro
por: Watson, Christopher P., et al.
Publicado: (2016)

Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study
por: Xuan, Chao, et al.
Publicado: (2016)

Urinary Dimethylamine (DMA) and Its Precursor Asymmetric Dimethylarginine (ADMA) in Clinical Medicine, in the Context of Nitric Oxide (NO) and Beyond
por: Tsikas, Dimitrios
Publicado: (2020)

Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis
por: Wu, Yizheng, et al.
Publicado: (2023)

Author Correction: The role of asymmetric dimethylarginine (ADMA) in COVID-19: association with respiratory failure and predictive role for outcome
por: Sozio, Emanuela, et al.
Publicado: (2023)

Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway
por: Lee, Tzong-Shyuan, et al.
Publicado: (2021)

Do We Need a Specific Guideline for Assessment and Improvement of Acromegaly Patients Adherence?
por: Kamusheva, Maria, et al.
Publicado: (2021)

Multivariate Statistical Approach for Nephrines in Women with Obesity
por: Robeva, Ralitsa, et al.
Publicado: (2021)

Effect of Lowering Asymmetric Dimethylarginine (ADMA) on Vascular Pathology in Atherosclerotic ApoE-Deficient Mice with Reduced Renal Mass
por: Jacobi, Johannes, et al.
Publicado: (2014)

Positive correlation of airway resistance and serum asymmetric dimethylarginine (ADMA) in bronchial asthma patients lacking evidence for systemic inflammation
por: Tajti, Gabor, et al.
Publicado: (2018)

Serum Levels of Asymmetric Dimethylarginine and Apelin as Potential Markers of Vascular Endothelial Dysfunction in Early Rheumatoid Arthritis
por: Di Franco, Manuela, et al.
Publicado: (2012)

Asymmetric Dimethylarginine as a Surrogate Marker of Endothelial Dysfunction and Cardiovascular Risk in Patients with Systemic Rheumatic Diseases
por: Dimitroulas, Theodoros, et al.
Publicado: (2012)

Urinary excretion of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine is positively related to nitric oxide level in tissues of normotensive and hypertensive rats
por: Szlęzak, Dominika, et al.
Publicado: (2023)

The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine
por: Taghikhani, Emir, et al.
Publicado: (2019)

Asymmetric dimethylarginine (ADMA) accelerates renal cell fibrosis under high glucose condition through NOX4/ROS/ERK signaling pathway
por: Jayachandran, Isaivani, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_50g0519balpi4498m2d7kr2689